Pharmaceutical Dissolution Testing Products and Services

Dissolution testing allows for the examination and prediction of the in-vitro behavior of pharmaceutical formulations. Drug release behavior of pre-formulations is made possible by the use of specialized dissolution equipment. By dissolution testing, a researcher can simulate the behavior of capsule, bead, and enteric-coated tablets in-vitro.

Important Applications of Dissolution Testing

  • Quality Control
  • Replicating certain mechanisms of in-vitro drug release
  • Determining if drug behavior meets regulatory standards
  • Dissolution simulation when choosing pharmaceutical excipients

Examples of Pharmaceutical Dissolution Equipment

Paddle apparatus dissolution testing is used to simulate tablet behavior in the gastrointestinal tract. The release behavior of implants and transdermal medications can also be tested with dissolution equipment. The reciprocating cylinder dissolution apparatus ("Bio-Dis") is excellent for examining the dissolution behavior of extended release products. Dissolution analysis is key in determining the homogeneity of the final pharmaceutical product. Whether controlled by the bench user or fully automated, the implementation of a dissolution testing protocol is crucial in the final stages of drug development to ensure the efficacy, safety, and marketability of the final compound.
  • The Next Test for AI in Pharmacovigilance Is Trust, Not Accuracy

    Monday, September 21, 2026
    An AI model can be right and still not be trusted. That’s what Bristol Myers Squibb (BMS) found six months into rolling out AI-powered adverse event processing: while F1 performance scores were tracking upward, the audit trail found reviewers still reopening cases the system had already cleared. read more
  • Rethinking Early-Phase Outsourcing

    Monday, September 21, 2026
    The CDMOs that bridge the fulfilment gap and truly become partners are likely the best choice for biotechs and pharma looking to develop their early-stage asset. While most CDMOs are well-versed in providing services with regular communication, sharing strategic objectives with clients, and ... read more
  • Horizon Lines: A Quarterly Review of NDAs – April to June 2026

    Monday, September 21, 2026
    This quarterly review on New Drug Applications contains data for applications approved for the first time during the second quarter of 2026, which includes New Molecular Entities (NMEs) and new biologics. read more
  • The Human Advantage in ADME Testing

    Friday, September 18, 2026
    Animal models do not accurately recapitulate several aspects of human physiology, and these differences lead to variations in drug behaviors across species. Each contributes useful evidence, but what is missing is the connected human biology needed to predict ADME behavior with confidence. read more
  • Upperton Receives MHRA License for Sterile Manufacturing Facility

    Thursday, September 17, 2026
    Upperton has received approval from the U.K. Medicines and Healthcare products Regulatory Agency for a variation to its Manufacturing and Importation Authorisation for Investigational Medicinal Products license covering a new sterile manufacturing facility in Nottingham. read more
We're sorry, no matching articles were found. Please select different filter options and try your search again.
We're sorry, no matching articles were found. Please select different filter options and try your search again.